摘要
目的探讨对恶性腹腔积液进行血清铁蛋白、同型半胱氨酸和D-二聚体的联合检测的临床价值。方法选取2017年1月至2022年12月于我院就诊的恶性腹腔积液患者100例作为研究对象,另选取80例健康志愿者作为阴性对照组。采用血清铁蛋白(serum ferritin,SF)、同型半胱氨酸(homocysteine,Hcy)、D-二聚体(D-Dimer,D-D)联合检测对不同病因的恶性腹腔积液的疗效评价,将获得完全缓解和部分缓解的患者纳入实验组,其余为对照组。测量数据以均数和标准差表示,利用ROC曲线下面积(AUC)和最佳截断值对恶性腹腔积液的疗效进行多组间比较分析。结果恶性腹腔积液患者SF、Hcy、D-D联合检查水平均明显高于对照组(P<0.001),水平与恶性腹腔积液程度有关(P<0.05),原因不同。血清水平经治疗后明显降低(P<0.001),24例患者经治疗后病情减轻。实验组患者治疗前血清SF、Hcy、D-D联合检测水平显著低于对照组(P<0.001)。结论SF、Hcy、D-D联合检测可对恶性腹腔积液治疗的反应性及预后进行谨慎预测。
Objective To analyze the clinical value of combined detection of serum ferritin,homocysteine and D-dimer in malignant ascites.Methods 100 patients with malignant ascites admitted to our hospital from January,2017 to December,2021 were selected as the study subjects,while 50 healthy volunteers were selected as the control group.The efficacy evaluation of combining serum ferritin(SF),homocysteine(Hcy),and D-dimer(D-D)detection for malignant peritoneal effusion of different causes was conducted.Patients who achieved complete or partial remission were included in the experimental group,while the rest were included in the control group.The measured data were expressed as mean standard deviation,and t-test was used to compare the efficacy of malignant ascites across multiple groups.ROC curve was drawn to calculate the area under the curve(AUC)and to identify the optimal cutoff value.Results The combined detection levels of SF,Hcy,and D-D in patients with malignant ascites were significantly higher than those in the control group(P<0.001),and the levels were related to the levels of malignant ascites of different causes(P<0.05).After treatment,serum levels significantly decreased(P<0.001),and 24 patients achieved remission.The combined detection level of serum SF,Hcy and D-D in the experimental group before treatment was significantly lower than that in the control group(P<0.001).Conclusion Combined detection of SF,Hcy and D-D can be used to evaluate the response and prognosis of malignant ascites.
作者
王虎明
高玉骞
李丽莉
徐杰
WANG Huming;GAO Yuqian;LI Lili;XU Jie(Laboratory Department,Baotou Cancer Hospital,Baotou 014030,China;Department of Gastroenterology,Baotou Cancer Hospital,Baotou 014030,China;Department of Surgical Oncology,Baotou Cancer Hospital,Baotou 014030,China)
出处
《标记免疫分析与临床》
CAS
2023年第7期1145-1148,1176,共5页
Labeled Immunoassays and Clinical Medicine
基金
中华人民共和国国家发展和改革委员会,2019年增强制造业核心竞争力专项“国产高端血凝分析系统研发及产业化”子课题-血浆D-二聚体测定与实体肿瘤相关性研究(编号:2019X000G038)。